Two-receptor incretin agonists changed the trajectory of metabolic peptide design almost overnight. Now the field has already moved to the next frontier: triple receptor agonists that engage GLP-1R, GIPR, and GCGR simultaneously within a single peptide backbone. Building a molecule that can hit three distinct class B GPCRs with balanced, tunable potency is a genuinely hard computational and medicinal chemistry problem, and it’s reshaping how researchers think about metabolic peptide architecture.
This article walks through the computational design strategies behind next-generation triple hormone receptor agonists, the push toward once-monthly exposure candidates such as ASC37, and the persistent challenge of balancing potency ratios across three receptor targets at once.
The Case for a Third Receptor
GLP-1 receptor agonism drives glucose-dependent insulin secretion and appetite-related signaling, while GIP receptor engagement appears to modulate adipocyte biology and may counteract some of the nausea-associated signaling seen with GLP-1-heavy exposure in research models. Adding glucagon receptor (GCGR) activity introduces an energy-expenditure component through hepatic glycogenolysis and increased metabolic rate, at least in rodent models where this has been most thoroughly characterized. The combined hypothesis is straightforward on paper: stack complementary mechanisms into one molecule and you may achieve additive or synergistic effects on body weight-related endpoints beyond what any single-receptor or even dual-receptor agonist can reach.
Retatrutide, one of the earlier triple agonists to generate substantial research interest, reported body weight reductions in Phase 2 study data that outpaced many dual agonists tested in comparable populations. That result alone justified a wave of follow-on triple agonist design programs.
Computational Design for Metabolic Stability
Native GLP-1, GIP, and glucagon peptides share structural homology but differ enough in sequence that engineering a single backbone to activate all three receptors requires careful residue-by-residue optimization. Computational approaches now commonly used include molecular dynamics simulation of receptor-ligand complexes, machine learning-guided sequence optimization trained on binding affinity datasets, and rational substitution at positions known to affect protease resistance.
Protecting Against Enzymatic Degradation
Native incretin peptides get cleaved rapidly by dipeptidyl peptidase-4 (DPP-4) at the position 2 alanine, which is why nearly every modern design substitutes that residue with a non-natural amino acid such as aminoisobutyric acid (Aib). This single substitution alone can extend circulating half-life from single-digit minutes to multiple hours in research models. Combine that with a fatty acid or fatty diacid conjugation strategy for albumin binding : the same lipidation logic used in earlier long-acting GLP-1 designs : and you start approaching the multi-day half-lives needed for infrequent exposure schedules.
Toward Once-Monthly Exposure Candidates
ASC37 and related investigational compounds represent an attempt to push exposure intervals from weekly to monthly, primarily through more extensive lipidation and structural modification aimed at slowing both renal clearance and receptor-mediated internalization. Achieving a true once-monthly profile requires an elimination half-life substantially longer than what weekly agonists currently exhibit, and researchers have reported half-life figures extending well beyond a week in early-stage pharmacokinetic study data for some monthly-exposure candidates.
Is a monthly schedule actually better for metabolic outcomes, or does it simply trade convenience for a flatter, less physiologically dynamic exposure curve? That’s an open question that ongoing Phase 2 study programs should help clarify as more comparative data accumulates.
Balancing Three-Receptor Potency Ratios
Perhaps the hardest part of triple agonist design isn’t hitting all three receptors : it’s hitting them in the right relative proportion. Too much GCGR activity relative to GLP-1R activity can drive glucose-dependent effects that work against glycemic control in research models, since glucagon signaling raises hepatic glucose output. Too little GIP engagement may fail to deliver the additive adipose tissue effects that motivated adding the receptor in the first place.
- GLP-1R-dominant designs tend to prioritize glycemic and appetite-related signaling
- Balanced GLP-1R/GCGR ratios aim to combine appetite suppression with elevated energy expenditure
- GIPR contribution is generally the hardest to isolate functionally in in-vivo research models
Reported EC50 values across in vitro reporter assays for candidates like retatrutide and newer molecules show single-digit to double-digit picomolar potency at GLP-1R, with somewhat higher (less potent) EC50 values typically reported at GCGR, reflecting deliberate design choices rather than incidental imbalance.
Species Translation and Model Considerations
A recurring complication in this research area: rodent and non-human primate receptor sequences don’t always predict human receptor pharmacology precisely, particularly for GCGR, where species-specific differences in extracellular loop structure can shift binding behavior. Diet-induced obese mouse models remain the standard first screen for body weight-related endpoints, but translating relative receptor potency ratios from mouse to human study contexts requires additional in vitro cross-species binding characterization before advancing a candidate further.
Research Outlook
Triple hormone receptor agonist design sits right at the intersection of structural biology, computational chemistry, and metabolic physiology, and the pace of new candidate disclosures hasn’t slowed. Expect continued refinement of lipidation chemistry, more sophisticated machine learning models trained on expanding binding datasets, and deeper mechanistic work clarifying exactly how GIPR contributes to the overall metabolic effect profile. Whether four-receptor designs are next remains genuinely uncertain, but the trajectory of this field suggests investigators aren’t done adding complexity in pursuit of better balanced pharmacology.
Disclaimer: This content is intended for research purposes only and is not meant to constitute medical advice.
This educational material discusses laboratory research concepts only. Loti Labs products are intended strictly for research and development use and are not for human consumption.
